Neanderthal gene variants may cause Viking disease

A new study suggests that the so-called Viking disease, which affects the hand function in many older people, may be linked to gene variants inherited from Neanderthals.

Microscope and measuring machine in one

ZEISS O-INSPECT duo covers two essential applications in quality assurance.

A mass flow controller that is silent, fast and cost-effective

Portable ventilator breathing devices, bioreactors or the dosing of inert gases all rely on the highest control dynamics. That is exactly what the proportional ...

Bought a tablet factory – and built his own empire

In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move i...

The dock that “thinks” for itself

The world of bulk material handling seems straightforward at first glance: moving, filling, delivering. However, the art of dealing with a variety of different ...

Marie Gårdmark: ”The situation is not satisfactory”

”The legislative tool-box is limited, but carrots in the form of longer exclusivity has already proven successful, this has for example increased registration o...

Advancing 3D Culture Imaging: Insights from Academia, Biotech, and Pharma

Webinar | March 13, 2024, 12 PM EST.

She creates pharmaceuticals on a 3D printer

The correct dosage for each individual, regardless of whether the pharmaceutical is for a seriously ill child or a frail elderly person, is the mission of a wel...

Marie Gårdmark: Potential step change – EU regulators get to play with data

A new pilot from EMA is starting in September to assess wether the analysis of 'raw data' by regulatory authorities improves the evaluation of marketing approva...

Extremely high sample throughput rates

Precision and reliability in automated liquid handling

Uppsala-based company wins important patent dispute – but the decision is subject to appeal

and has filed an appeal.

Learn from Speakers from Leading MedTech Companies

Watch the recordings from ZEISS Quality Innovation Days whenever it suits you.

Affibody AB

Study: Cancer vaccine prolongs survival in difficult-to-treat tumour disease

According to a new study, a combination of a cancer vaccine from Norwegian company Ultimovacs and two immunotherapies significantly prolonged survival in cases ...

Introduction of ZEISS Imaging Systems for Super-Resolution

Webinar recording about the ZEISS Lattice SIM technology.

Medical device quality assurance

Recordings from ZEISS Quality Innovation Days.

Major investment in women’s health – for a more equal healthcare system

”The regional differences need to decrease and the long-term supply of midwives and other professions needs to be secured,” write Acko Ankarberg Johansson and D...

Anna Törner: To kill your darlings

Hopes were high when Anna Törner and her colleague started a study on a dietary supplement that seemed unbelievably good. “Enthusiastically, we dreamed of excit...

Karolinska Development tar in kapital – och byter namn

Life science-investmentbolaget Karolinska Development föreslår en företrädesemission om cirka 203 miljoner kronor före transaktionskostnader.

Svenskt biotechbolag tar in 153 miljoner till cancerstudie

One-carbon Therapeutics, ett svenskt biotechbolag med inriktning på svårbehandlad cancer, har tagit in 153 miljoner kronor i en övertecknad investeringsrunda.

Lundbeck kliver in i budstrid om narkolepsibolag

En budstrid har brutit ut om det irländska biotechbolaget Avadel Pharmaceuticals och dess potentiella storsäljare inom narkolepsi och hypersomni.

Samuel Lagercrantz: A special kind of hellishness afflicts post-COVID patients

In addition to the disease itself those suffering from post-COVID have to deal with people who try to label them as hypochondriacs, writes Samuel Lagercrantz in an editorial.

Double up for Korbinian Löbmann

This year, Korbinian Löbmann will moderate the New Updates in Drug Formulation & Bioavailability meeting in Copenhagen for the fifth time. Furthermore, he will ...

Nordic Regulatory experts: Improving biotech chances of Succ

Why is it that so many biotech companies fail? And what are the tools needed to change that fact?